Publication

Enhanced antitumor efficacy of a dr5-specific trail variant over recombinant human trail in a bioluminescent ovarian cancer xenograft model

Duiker, E. W.
de Vries, E. G.E.
Mahalingam, D.
Meersma, G. J.
Boersma-van Ek, W.
Hollema, H.
Lub-de Hooge, M. N.
van Dam, G. M.
Cool, R. H.
Quax, W. J.
... show 3 more
Citation
Duiker, E. W. de Vries, E. G.E.; Mahalingam, D.; Meersma, G. J.; Boersma-van Ek, W.; Hollema, H.; Lub-de Hooge, M. N.; van Dam, G. M.; Cool, R. H.; Quax, W. J.; Samali, A.; van der Zee, A. G.J.; de Jong, S. (2009). Enhanced antitumor efficacy of a dr5-specific trail variant over recombinant human trail in a bioluminescent ovarian cancer xenograft model. Clinical Cancer Research 15 (6), 2048-2057
Abstract
Purpose: Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (rhTRAIL) is clinically evaluated as novel anticancer drug. rhTRAIL-DR5, a rhTRAIL variant that specifically binds to DR5 receptor, has recently been developed. We investigated whether rhTRAIL-DR5 is more efficient than rhTRAIL in combination with cisplatin in DR5-expressing human A2780 ovarian cancer cells. Design: Effect of cisplatin alone or in combination with rhTRAIL or rhTRAIL-DR5 on DR5 surface expression, apoptosis, and cell survival of A2780 was measured. Biodistribution analysis was done in mice with I-125-rhTRAIL administered intravenously versus intraperitoneally. Antitumor efficacy of rhTRAIL-DR5 versus rhTRAIL was determined in an intraperitoneally growing bioluminescent A2780 xenograft model. Results: Cisplatin strongly enhanced DR5 surface expression. Both rhTRAIL and rhTRAIL-DR5 in combination with cisplatin induced high levels of caspase-3 activation, apoptosis, and cell kill, with rhTRAIL-DR5 being most potent. Intraperitoneal administration of I-125-rhTRAIL resulted in a 1.7-fold higher area under the curve in serum, increased tumor exposure, and more caspase-3 activation in the tumor than intravenous administration. Intraperitoneal administration of rhTRAIL-DR5 delayed A2780 tumor progression, reflected in a mean light reduction of 68.3% (P = 0.015), whereas rhTRAIL or rhTRAIL-DR5 plus cisplatin resulted in 85% (P = 0.003) and 97% (P = 0.002) reduction compared with A2780 tumor progression in vehicle-treated animals. Combination of rhTRAIL-DR5 with cisplatin was more effective than cisplatin alone (P = 0.027). Conclusion: rhTRAIL-DR5 was superior over rhTRAIL in vitro and in vivo against DR5-expressing ovarian cancer also in combination with cisplatin. Intraperitoneal administration of rhTRAIL-DR5 warrants further exploration in ovarian cancer.
Funder
Publisher
American Association for Cancer Research (AACR)
Publisher DOI
10.1158/1078-0432.ccr-08-1535
Rights
Attribution-NonCommercial-NoDerivs 3.0 Ireland